Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Alphatec designs, develops, manufactures, and markets spinal surgery implants. The company operates primarily in the United States and Japan. It is a holding company with no operations of its own; its principal asset is the stock of its subsidiary, Alphatec Spine, Inc.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2006 | Nine Months Ended Sept 30, 2006 | Three Months Ended Sept 30, 2005 | Nine Months Ended Sept 30, 2005 |
|---|---|---|---|---|
| Revenues | $17,358 | $54,809 | $11,527 | $26,748 |
| Gross Profit | $10,752 | $35,226 | $6,543 | $15,958 |
| Gross Margin | 61.9% | 64.3% | 56.8% | 59.7% |
| Operating Loss | $(5,609) | $(12,530) | $(4,452) | $(10,690) |
| Net Loss | $(5,438) | $(14,492) | $(3,489) | $(9,450) |
| Net Loss per Share (Basic/Diluted) | $(0.16) | $(0.72) | $(0.29) | $(0.73) |
| Cash and Cash Equivalents (Sept 30, 2006) | $21,360 | |||
| Total Debt (Current + Long-term) | $4,578 |
Note: Debt includes lines of credit ($1,696), current portion of long-term debt ($2,333), and long-term debt ($2,882). No borrowings were outstanding under the $10.0 million Bank of the West revolving credit facility as of September 30, 2006.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 51% ($5.8 million) for the three months and 105% ($28.1 million) for the nine months ended September 30, 2006, compared to the same periods in 2005. Growth was driven by expanded sales networks in the U.S. and Japan, and the acquisition of Cortek, Inc. in September 2005.
- Expense Increases: Operating expenses rose significantly due to sales force expansion, new product development, and public company costs. Sales and marketing expenses increased 69% ($3.5 million) for the quarter and 96% ($11.3 million) for the nine months.
- Stock-Based Compensation: The company adopted SFAS No. 123(R) on January 1, 2006, resulting in recognized stock-based compensation of $1.2 million for the quarter and $4.7 million for the nine months ended September 30, 2006.
- One-Time Items: The 2005 period included a $3.1 million non-cash charge for in-process research and development (IPR&D) related to the acquisition of Alphatec Spine, which was not present in 2006.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management anticipates continuing net losses for the foreseeable future as it invests in sales, marketing, and R&D. The company believes current cash and credit facilities are sufficient to fund operations through 2007.
- Recent IPO: In June 2006, the company completed an IPO raising $70.2 million in net proceeds. Proceeds were used to redeem preferred stock ($35.2 million), reduce debt ($11.0 million), and fund working capital and growth initiatives.
- Proposed Acquisition: On September 27, 2006, the company entered into agreements to acquire a controlling interest (74.1%) in Scient'x, S.A., a French medical device manufacturer, for approximately $126.7 million in cash and stock. The transaction is subject to shareholder approval and financing.
- Debt Covenants: As of September 30, 2006, the company was not in compliance with one covenant under its Bank of the West credit facility. A waiver was obtained in November 2006, resulting in an interest rate increase.
- Legal Proceedings:
- Patent Infringement: Biedermann Motech GmbH and Depuy Spine, Inc. sued Alphatec for patent infringement regarding Zodiac and Solanas products. A motion for a preliminary injunction was denied in October 2006.
- Royalty Dispute: Four surgeons sued for unpaid royalties on polyaxial screws. Mediation in October 2006 was unsuccessful.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting as of December 31, 2005, related to the year-end close process and staffing. Remediation efforts are ongoing.
Key Facts for Investor Verification
- Liquidity Position: Verify the sufficiency of the $21.4 million cash balance and the $8.5 million available under the Bank of the West credit facility to fund operations and the proposed Scient'x acquisition.
- Debt Covenant Compliance: Monitor the company's ability to maintain compliance with debt covenants, specifically regarding net loss limits and profitability ratios, to avoid default.
- Scient'x Acquisition Status: Track the progress of the proposed acquisition of Scient'x, S.A., including shareholder approval and financing conditions, as it represents a significant capital commitment.
- Legal Exposure: Assess the potential financial impact of ongoing patent litigation and royalty disputes, which could result in significant damages or injunctions.
- Internal Control Remediation: Confirm the effectiveness of remediation steps taken to address the material weakness in internal controls, as required by Sarbanes-Oxley Act provisions.